- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03055000
Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine
Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine
Background:
Mosquitos carry diseases that cause major health problems and death worldwide. The AGS-v vaccine targets proteins in mosquito saliva. This may help prevent many mosquito-borne diseases. It might also reduce the lifespan of the mosquito that bites the vaccinated person.
Objective:
To see if the AGS-v vaccine is safe in humans and how it affects the immune system.
Eligibility:
Healthy adults ages 18-50
Design:
Participants will be screened another study.
Participants will be randomly assigned to get either the vaccine with a booster vaccine, the vaccine without the booster, or a placebo. These are given through a needle in the upper arm.
Participants will have visits that include medical history, physical exam, and blood and urine tests:
Baseline: They will get the vaccine and be monitored for 2 hours.
Follow-up visits 1 and 2 weeks after baseline.
Visit 3 weeks after baseline: They will get the booster and be monitored for 2 hours.
Follow-up visits 1 and 2 weeks after booster visit.
Visit 3-5 weeks after booster visit: This includes mosquito feeding. Mosquitos grown in the lab will be allowed to bite the arm. Blood will be drawn 4 times in the 3 hours after the feeding.
Phone follow-up a few days after the mosquito feeding.
After the feeding visit, 5 follow-up visits about every 2 months
Participants will keep a symptom diary for 7 days after each vaccine. They will record their temperature. They will measure any redness around the injection site. They will document and if possible photograph any mosquito bites they get.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mosquito-borne diseases continue to cause significant morbidity and mortality worldwide despite on-going control efforts. In 2015, there were >200 million cases of malaria worldwide, causing nearly half a million deaths, with most of the deaths occurring among children under the age of 5 years. Mosquitos also transmit arboviruses, including dengue, yellow fever, West Nile virus, chikungunya, Rift Valley fever, Japanese encephalitis, and Zika virus. The current new outbreak of Zika virus in Central and South America, as well as the Caribbean, serves as a reminder of how quickly these viruses can spread and how difficult they can be to control.
In this protocol we plan to perform a Phase I study of a novel universal mosquito-borne disease vaccine. Through modulation of the immune system after a mosquito feeding, this vaccine targets the vector saliva and may provide prophylaxis against multiple arboviral and protozoal diseases. In addition the vaccine potentially leads to a reduced mosquito lifespan after feeding therefore also reducing transmission of these diseases.
In this protocol we hope to demonstrate the safety of this vaccine similar to SEEK s other peptide based vaccines Flu-v and HIV-v that have been found to have very good safety profiles in previous Phase I trials. We also hope to demonstrate immunomodulation after a controlled clean Aedes aegypti mosquito feeding to demonstrate proof of concept efficacy of the vaccine. With the current rise of Zika in the Americas and the threat of local mosquito transmission in the U.S. and the rest of the world, a successful universal mosquito-borne disease vaccine offers the benefit of targeting this emerging disease as well as the many established infections such as dengue and malaria that make dealing with this newly emerging epidemic a challenge.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
-INCLUSION CRITERIA:
- Healthy women and men who are greater than or equal to 18 and less than or equal to 50 years of age.
- Willingness to complete all study visits and comply with all study requirements.
- A male subject is eligible for the study if he agrees to practicing abstinence or using a condom with spermicide plus an acceptable form of contraception (see inclusion criteria 4) being used by any female partner from 4 weeks before study start to 12 weeks after the second vaccine administration.
A female participant is eligible for this study if she is not pregnant or breast feeding and 1 of the following:
- Of non-child bearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses in greater than or equal to 1 year).
- Of childbearing potential but agrees to practice effective contraception or abstinence for 4 weeks prior to study initiation through 12 weeks after the second vaccine administration. Acceptable methods of contraception include a male partner who is sterile and is the sole sexual partner of the female participant or a male partner who uses a condom with spermicide plus 1 or more of the following: 1) implants of levonorgestrel; 2) injectable progestogen; 3) an intrauterine device with a documented failure rate of <1%; 4) oral contraceptives; and 5) double barrier method including diaphragm.
- Willing to have samples stored for future research (including genetic research).
- Agrees to abstain from alcohol intake for 24 hours prior to each study visit.
- Agrees to not donate blood or blood products throughout the study.
EXCLUSION CRITERIA:
- Participant has any underlying or current medical condition, which, in the opinion of the Investigator, would interfere with the participation in the study.
- Individual with body mass index (BMI) less than or equal to 18 and greater than or equal to 40.
- Participants who have a clinically significant (as determined by the PI) baseline Grade 1 or greater toxicity, or any Grade 3 or greater toxicity (regardless of clinical significance) by the toxicity table.
- Receipt of blood or blood products (including immunoglobulins) within 3 months prior to enrollment.
- Receipt of any unlicensed drug within 3 months or 5.5 half-lives (whichever is greater) prior to enrollment.
- Receipt of any unlicensed vaccine within 6 months prior to enrollment.
- Self-reported or known history of alcoholism or drug abuse within 6 months prior to enrollment, or positive urine/serum test for drugs of abuse at screening
- Self-reported or known history of psychiatric or psychological issues that require treatment and are deemed by the PI to be a contraindication to protocol participation.
- History of a previous severe allergic reaction with generalized urticaria, angioedema, anaphylaxis or anaphylactoid reaction.
- Any condition or event that, in the judgment of the PI, is a contraindication to protocol participation or impairs the volunteer's ability to give informed consent.
- Has a known allergy to any of the components of the vaccine.
- Has a history of severe immunization reaction.
- Has a severe allergic reaction to mosquito bites
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AGS-v
AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
|
AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
|
Experimental: AGS-v with adjuvant
ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL)on Day 0 and on Day 21
|
ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21
|
Placebo Comparator: Placebo
WFI (0.5mL) on Day 0 and Day 21
|
WFI (0.5mL) on Day 0 and Day 21
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AEs Grade 3 or Higher
Time Frame: 1 year after vaccination (study duration)
|
Grade 3 or higher adverse events identified within 1 year after 2 vaccinations 21 days apart.
|
1 year after vaccination (study duration)
|
GM-CSF Cytokine Level as Measured by Luminex
Time Frame: 21 days after last vaccination
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
21 days after last vaccination
|
IL-10 Cytokine Level as Measured by Luminex
Time Frame: 21 days after last vaccination
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
21 days after last vaccination
|
IL-1B Cytokine Level as Measured by Luminex
Time Frame: 21 days after last vaccination
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
21 days after last vaccination
|
IL-2 Cytokine Level as Measured by Luminex
Time Frame: 21 days after last vaccination
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
21 days after last vaccination
|
IL-4 Cytokine Level as Measured by Luminex
Time Frame: 21 days after last vaccination
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
21 days after last vaccination
|
IL-5 Cytokine Level as Measured by Luminex
Time Frame: 21 days after last vaccination
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
21 days after last vaccination
|
Interferon-gamma Cytokine Level as Measured by Luminex
Time Frame: 21 days after last vaccination
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
21 days after last vaccination
|
Number of Subjects With 1 or More Aes
Time Frame: 1 year after vaccination (study duration)
|
Percent of people with an AE
|
1 year after vaccination (study duration)
|
Number of Subjects With 1 or More Grade 3 or Higher AE
Time Frame: 1 year after vaccination (study duration)
|
Percent of people with a Grade 3 or higher AE
|
1 year after vaccination (study duration)
|
TNF-a Cytokine Level as Measured by Luminex
Time Frame: 21 days after last vaccination
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
21 days after last vaccination
|
Total AGS-v Specific Immunoglobulin
Time Frame: 21 days after last vaccination
|
Total AGS-v specific immunoglobulin measured in serum 14 days after the first and/or second vaccination.
|
21 days after last vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GM-CSF Cytokine Level as Measured by Luminex
Time Frame: 60 days after Day 42 Mosquito Feeding
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
60 days after Day 42 Mosquito Feeding
|
IL-10 Cytokine Level as Measured by Luminex
Time Frame: 60 days after Day 42 Mosquito Feeding
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
60 days after Day 42 Mosquito Feeding
|
IL-1B Cytokine Level as Measured by Luminex
Time Frame: 60 days after Day 42 Mosquito Feeding
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
60 days after Day 42 Mosquito Feeding
|
IL-2 Cytokine Level as Measured by Luminex
Time Frame: 60 days after Day 42 Mosquito Feeding
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
60 days after Day 42 Mosquito Feeding
|
IL-4 Cytokine Level as Measured by Luminex
Time Frame: 60 days after Day 42 Mosquito Feeding
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
60 days after Day 42 Mosquito Feeding
|
IL-5 Cytokine Level as Measured by Luminex
Time Frame: 60 days after Day 42 Mosquito Feeding
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
60 days after Day 42 Mosquito Feeding
|
Interferon-gamma Cytokine Level as Measured by Luminex
Time Frame: 60 days after Day 42 Mosquito Feeding
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
60 days after Day 42 Mosquito Feeding
|
Number of Adults Developed From 100 Eggs
Time Frame: Day 42 Mosquito feeding
|
Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination
|
Day 42 Mosquito feeding
|
Number of Eggs Laid
Time Frame: Day 42 Mosquito feeding
|
Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination
|
Day 42 Mosquito feeding
|
Number of Pupae Hatched of 100 Eggs
Time Frame: Day 42 Mosquito feeding
|
Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination
|
Day 42 Mosquito feeding
|
Percent of Eggs That Developed Into Pupae
Time Frame: Day 42 Mosquito feeding
|
Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination
|
Day 42 Mosquito feeding
|
Percent of Pupae That Developed Into Adults
Time Frame: Day 42 Mosquito feeding
|
Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination
|
Day 42 Mosquito feeding
|
TNF-a Cytokine Level as Measured by Luminex
Time Frame: 60 days after Day 42 Mosquito Feeding
|
Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response
|
60 days after Day 42 Mosquito Feeding
|
Total AGS-v Specific Immunoglobulin
Time Frame: 60 days after Day 42 Mosquito Feeding
|
Total AGS-v specific immunoglobulin measured in serum after the first and/or second vaccination.
|
60 days after Day 42 Mosquito Feeding
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Peng Z, Yang M, Simons FE. Immunologic mechanisms in mosquito allergy: correlation of skin reactions with specific IgE and IgG antibodies and lymphocyte proliferation response to mosquito antigens. Ann Allergy Asthma Immunol. 1996 Sep;77(3):238-44. doi: 10.1016/S1081-1206(10)63262-0.
- Sidjanski S, Vanderberg JP. Delayed migration of Plasmodium sporozoites from the mosquito bite site to the blood. Am J Trop Med Hyg. 1997 Oct;57(4):426-9. doi: 10.4269/ajtmh.1997.57.426.
- Ribeiro JM. Role of saliva in blood-feeding by arthropods. Annu Rev Entomol. 1987;32:463-78. doi: 10.1146/annurev.en.32.010187.002335. No abstract available.
- Manning JE, Oliveira F, Coutinho-Abreu IV, Herbert S, Meneses C, Kamhawi S, Baus HA, Han A, Czajkowski L, Rosas LA, Cervantes-Medina A, Athota R, Reed S, Mateja A, Hunsberger S, James E, Pleguezuelos O, Stoloff G, Valenzuela JG, Memoli MJ. Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial. Lancet. 2020 Jun 27;395(10242):1998-2007. doi: 10.1016/S0140-6736(20)31048-5. Epub 2020 Jun 11.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 170059
- 17-I-0059 (Other Identifier: NIAID)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mosquito-Borne Disease
-
National Institute of Allergy and Infectious Diseases...PepTcell Limited (t/a SEEK)CompletedMosquito-Borne Infectious DiseasesUnited States
-
Africa Power LimitedMalaria Consortium; ARCTECH INNOVATION LIMITEDNot yet recruitingMalaria | Mosquito-Borne Disease
-
Institut PasteurMinistry of Health of Vanuatu; Vanuatu National HospitalRecruitingCOVID-19 | Dengue | Chikungunya | Zika | Ross River | Arbovirus DiseaseVanuatu
-
National Institute of Allergy and Infectious Diseases...Recruiting
-
National Institute of Allergy and Infectious Diseases...Suspended
-
Malaria ConsortiumActive, not recruiting
-
National Institute of Allergy and Infectious Diseases...Completed
-
University of OxfordGlobal FundCompleted
-
BioNTech SEActive, not recruiting
-
National Institute of Allergy and Infectious Diseases...Active, not recruiting
Clinical Trials on AGS-v
-
McGill University Health Centre/Research Institute...Université de Montréal; Argos TherapeuticsCompletedAcquired Immunodeficiency Syndrome | HIV SeropositivityCanada
-
Agensys, Inc.CompletedCarcinoma, Renal Cell | Renal Cell Carcinoma of Papillary Histology | Renal Cell Carcinoma With Clear Cell Histology | Renal Cell Carcinoma With Non-Clear Cell HistologyUnited States, Canada
-
Astellas Pharma IncAgensys, Inc.CompletedCarcinoma | Ovarian Diseases | Ovarian Neoplasms | Ovarian CancerUnited States
-
Astellas Pharma IncAgensys, Inc.TerminatedKidney Neoplasms | Carcinoma, Renal Cell | Kidney DiseasesUnited States
-
Astellas Pharma IncAgensys, Inc.CompletedRenal Cell Carcinoma | Pharmacokinetics of AGS-16M8FUnited States
-
Argos TherapeuticsCompletedInflammation | Systemic Lupus Erythematosus (SLE)United States
-
Argos TherapeuticsCompletedHIV InfectionUnited States, Canada
-
Astellas Pharma IncSeagen Inc.; Agensys, Inc.CompletedNeoplasms | Tumors | Medical OncologyUnited States, Canada
-
Ahn-Gook Pharmaceuticals Co.,LtdCompletedAcute BronchitisKorea, Republic of